Septerna, Inc. (SEPN)
NASDAQ:SEPN
Want to see SEPN full AI Analyst Report?
SEPN Stock Chart & Stats
$26.13
$0.38(1.86%)
At close: 4:00 PM EST
$26.13
$0.38(1.86%)
Day’s Range― - ―
52-Week Range$9.85 - $32.63
Previous CloseN/A
Volume49.14K
Average Volume (3M)323.51K
Market Cap
$1.40B
Enterprise Value$1.31B
Total Cash (Recent Filing)$347.40M
Total Debt (Recent Filing)$23.09M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 17, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding45,075,535
10 Day Avg. Volume311,485
30 Day Avg. Volume323,509
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue18.17
Enterprise Value/Gross Profit18.27
Enterprise Value/Ebitda-19.72
Forecast
1Y Price Target
$44.40Price Target Upside69.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$74.06M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationThe shift to strongly positive operating and free cash flow in 2025 and TTM 2026 materially reduces near-term funding risk and supports ongoing R&D without immediate reliance on dilutive financing. Sustained cash generation provides durable runway to advance trials and partnerships over the next several quarters.
Conservative Balance SheetLow leverage and a sizable equity base give Septerna flexibility to fund clinical programs, absorb trial setbacks, and pursue collaborations. A conservatively levered balance sheet supports strategic choices and reduces refinancing risk over a multi-quarter horizon.
Pipeline Progress And Revenue MomentumAdvancing SEP-479 into dosing and SEP-631 into later development demonstrates tangible pipeline de-risking and validates the discovery engine. Combined with sharply accelerating revenue in 2025–TTM 2026, these developments strengthen long-term commercial potential and justify continued R&D investment.
Bears Say
Persistent Operating LossesDespite cash flow improvements, the firm continues to run large operating losses and negative net margins, indicating core operations do not yet cover fixed costs. Over the medium term this constrains profitability prospects, pressures returns, and could necessitate ongoing investment that limits near-term earnings improvement.
Negative Returns On EquitySustained negative ROE means the equity base has not produced profitable returns, undermining the quality of shareholder capital. If losses persist, equity value may be eroded and long-term investor returns will depend heavily on successful commercialization of pipeline assets.
Early-Stage Clinical RiskThe company's value is concentrated in early-stage programs with long timelines and binary clinical outcomes. Success requires positive trial readouts and regulatory progress; failure or delays would materially impair future revenue and make current cash generation less durable as a basis for long-term growth.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $9.85 and its highest was $32.63 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.40B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 70 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on May 11, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.227.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.44.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 45,075,535 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 5.388%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.40 (69.92% Upside)
$44.40 (69.92% Upside)
Blogger Sentiment
Bullish
SEPN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 620.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
196.10%
12-Months-Change
Fundamentals
Return on Equity
-9.44%
Trailing 12-Months
Asset Growth
31.26%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$44.40
▲(69.92% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
―
Ownership Overview
6.33% Insiders
7.89% Mutual Funds
77.57% Other Institutional Investors
1.60% Public Companies and
Individual Investors